Hematology

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

We highlighted a few cell and gene therapies that are nearing or likely nearing key FDA decisions in the first half of 2026.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about the potential of AI to affect development and use of cell and gene therapy products.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on cost reduction for cell and gene therapy products.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed their thoughts on the field's future.

Recapping some the FDA approvals and regulatory updates in cell and gene therapy that made waves in 2025.

Review top news and interview highlights from the week ending December 19, 2025.

Steven W. Pipe, MD, a professor of pediatric hematology/oncology at the University of Michigan Health, also discussed open questions that remain for the future of the hemophilia B gene therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on the importance of big wins for those in research.

Steven W. Pipe, MD, a professor of pediatric hematology/oncology at the University of Michigan Health, discussed the final results of the phase 3 study that evaluated the hemophilia B gene therapy.

Rabi Hanna, MD, the chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's, discussed results from the phase 1/2 RUBY trial.

Review top news and interview highlights from the week ending December 12, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The Fondazione Telethon agent, etuvetidigene autotemcel, significantly reduced severe infections and bleeding events in clinical studies.

Deevyashali Parekh, MBBS, an internal medicine resident at SUNY Upstate Medical University Hospital, discussed findings from a patient population traditionally excluded from clinical trials for CAR-T.

ImmunoLogic cohost Janna Minehart, MD, discussed a few exciting immunotherapy sessions she attended at ASH's Annual Meeting.

Crawford Strunk, MD, an associate staff member at the Cleveland Clinic, discussed the institution's experience with integrating use of exa-cel and lovo-cel.

Crawford Strunk, MD, an associate staff member at the Cleveland Clinic, discussed a study he presented at ASH’s 2025 Annual Meeting.

AZD0120, a dual-targeted CAR T-cell therapy, shows high efficacy in treating relapsed multiple myeloma, achieving a 96% response rate.

Review top news and interview highlights from the week ending December 5, 2025.

The agency's decision was based on results from an r/r MZL cohort in the phase 2 TRANSCEND FL clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed lessons that should guide the next generation of developers and regulators entering the field.

Review top news and interview highlights from the week ending November 28, 2025.